A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma (CONFIRM)

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: ae8a87bcd42d39ece52d9e4a5fc0e9a4f4772654
First added on: Jan 17, 2026